Effect of mesenchymal stem cells on peripheral immune cells in multiple sclerosis: results from an international phase 2 clinical trial.
INTRODUCTION The MESEMS trial was a randomized, double-blind, Placebo (Pbo)-controlled, crossover phase 2 study evaluating the safety and efficacy of autologous mesenchymal stromal cells (MSC) in multiple sclerosis (MS). Although the trial did not demonstrate a significant effect on MRI disease activity, MSC may exert...